Cargando…

Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs

BACKGROUND: Liver fibrosis can result in end-stage liver failure and death. AIM: To examine human liver fibrogenesis and anti-fibrotic therapies, we evaluated the three dimensional ex vivo liver slice (LS) model. METHODS: Fibrotic liver samples (F0 to F4 fibrosis stage according to the METAVIR score...

Descripción completa

Detalles Bibliográficos
Autores principales: Kartasheva-Ebertz, Daria, Gaston, Jesintha, Lair-Mehiri, Loriane, Massault, Pierre-Philippe, Scatton, Olivier, Vaillant, Jean-Christophe, Morozov, Vladimir Alexei, Pol, Stanislas, Lagaye, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934011/
https://www.ncbi.nlm.nih.gov/pubmed/33708350
http://dx.doi.org/10.4254/wjh.v13.i2.187
_version_ 1783660739700981760
author Kartasheva-Ebertz, Daria
Gaston, Jesintha
Lair-Mehiri, Loriane
Massault, Pierre-Philippe
Scatton, Olivier
Vaillant, Jean-Christophe
Morozov, Vladimir Alexei
Pol, Stanislas
Lagaye, Sylvie
author_facet Kartasheva-Ebertz, Daria
Gaston, Jesintha
Lair-Mehiri, Loriane
Massault, Pierre-Philippe
Scatton, Olivier
Vaillant, Jean-Christophe
Morozov, Vladimir Alexei
Pol, Stanislas
Lagaye, Sylvie
author_sort Kartasheva-Ebertz, Daria
collection PubMed
description BACKGROUND: Liver fibrosis can result in end-stage liver failure and death. AIM: To examine human liver fibrogenesis and anti-fibrotic therapies, we evaluated the three dimensional ex vivo liver slice (LS) model. METHODS: Fibrotic liver samples (F0 to F4 fibrosis stage according to the METAVIR score) were collected from patients after liver resection. Human liver slices (HLS) were cultivated for up to 21 days. Hepatitis C virus (HCV) infection, alcohol (ethanol stimulation) and steatosis (palmitate stimulation) were examined in fibrotic (F2 to F4) liver slices infected (or not) with HCV. F0-F1 HLS were used as controls. At day 0, either ursodeoxycholic acid (choleretic and hepatoprotective properties) and/or α-tocopherol (antioxidant properties) were added to standard of care on HLS and fibrotic liver slices, infected (or not) with HCV. Expression of the biomarkers of fibrosis and the triglyceride production were checked by quantitative reverse transcription polymerase chain reaction and/or enzyme-linked immunosorbent assay. RESULTS: The cultures were viable in vitro for 21 days allowing to study fibrosis inducers and to estimate the effect of anti-fibrotic drugs. Expression of the biomarkers of fibrosis and the progression to steatosis (estimated by triglycerides production) was increased with the addition of HCV and /or ethanol or palmitate. From day 15 of the follow-up studies, a significant decrease of both transforming growth factor β-1 and Procol1A1 expression and triglycerides production was observed when a combined anti-fibrotic treatment was applied on HCV infected F2-F4 LS cultures. CONCLUSION: These results show that the human three dimensional ex vivo model effectively reflects the in vivo processes in damaged human liver (viral, alcoholic, nonalcoholic steatohepatitis liver diseases) and provides the proof of concept that the LS examined model permits a rapid evaluation of new anti-fibrotic therapies when used alone or in combination.
format Online
Article
Text
id pubmed-7934011
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-79340112021-03-10 Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs Kartasheva-Ebertz, Daria Gaston, Jesintha Lair-Mehiri, Loriane Massault, Pierre-Philippe Scatton, Olivier Vaillant, Jean-Christophe Morozov, Vladimir Alexei Pol, Stanislas Lagaye, Sylvie World J Hepatol Basic Study BACKGROUND: Liver fibrosis can result in end-stage liver failure and death. AIM: To examine human liver fibrogenesis and anti-fibrotic therapies, we evaluated the three dimensional ex vivo liver slice (LS) model. METHODS: Fibrotic liver samples (F0 to F4 fibrosis stage according to the METAVIR score) were collected from patients after liver resection. Human liver slices (HLS) were cultivated for up to 21 days. Hepatitis C virus (HCV) infection, alcohol (ethanol stimulation) and steatosis (palmitate stimulation) were examined in fibrotic (F2 to F4) liver slices infected (or not) with HCV. F0-F1 HLS were used as controls. At day 0, either ursodeoxycholic acid (choleretic and hepatoprotective properties) and/or α-tocopherol (antioxidant properties) were added to standard of care on HLS and fibrotic liver slices, infected (or not) with HCV. Expression of the biomarkers of fibrosis and the triglyceride production were checked by quantitative reverse transcription polymerase chain reaction and/or enzyme-linked immunosorbent assay. RESULTS: The cultures were viable in vitro for 21 days allowing to study fibrosis inducers and to estimate the effect of anti-fibrotic drugs. Expression of the biomarkers of fibrosis and the progression to steatosis (estimated by triglycerides production) was increased with the addition of HCV and /or ethanol or palmitate. From day 15 of the follow-up studies, a significant decrease of both transforming growth factor β-1 and Procol1A1 expression and triglycerides production was observed when a combined anti-fibrotic treatment was applied on HCV infected F2-F4 LS cultures. CONCLUSION: These results show that the human three dimensional ex vivo model effectively reflects the in vivo processes in damaged human liver (viral, alcoholic, nonalcoholic steatohepatitis liver diseases) and provides the proof of concept that the LS examined model permits a rapid evaluation of new anti-fibrotic therapies when used alone or in combination. Baishideng Publishing Group Inc 2021-02-27 2021-02-27 /pmc/articles/PMC7934011/ /pubmed/33708350 http://dx.doi.org/10.4254/wjh.v13.i2.187 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Basic Study
Kartasheva-Ebertz, Daria
Gaston, Jesintha
Lair-Mehiri, Loriane
Massault, Pierre-Philippe
Scatton, Olivier
Vaillant, Jean-Christophe
Morozov, Vladimir Alexei
Pol, Stanislas
Lagaye, Sylvie
Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs
title Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs
title_full Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs
title_fullStr Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs
title_full_unstemmed Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs
title_short Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs
title_sort adult human liver slice cultures: modelling of liver fibrosis and evaluation of new anti-fibrotic drugs
topic Basic Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934011/
https://www.ncbi.nlm.nih.gov/pubmed/33708350
http://dx.doi.org/10.4254/wjh.v13.i2.187
work_keys_str_mv AT kartashevaebertzdaria adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs
AT gastonjesintha adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs
AT lairmehiriloriane adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs
AT massaultpierrephilippe adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs
AT scattonolivier adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs
AT vaillantjeanchristophe adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs
AT morozovvladimiralexei adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs
AT polstanislas adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs
AT lagayesylvie adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs